研究探析免疫球蛋白及补体的检测对乙肝肝硬化合并糖尿病患者的检测价值

Study on the Value of Immunoglobulin and Complement Detection in Patients with Hepatitis B Liver Cirrhosis and Diabetes

目的分析免疫球蛋白及补体的检测在乙肝肝硬化合并糖尿病患者中的检测价值。方法选取该院在2018年4月—2020年4月期间收治的乙肝肝硬化患者、糖尿病以及乙肝肝硬化合并糖尿病患者各33例作为研究对象,分别列为A、B、C 3组,采集3组患者的静脉血检测其免疫球蛋白及补体水平,比较3组患者的检测结果差异。结果在补体C3水平方面,C组患者和A组患者比较,组间数据差异无统计学意义(P>0.05),但是C组患者和B组患者比较,B组患者明显较C组患者高,差异有统计学意义(P<0.05);在补体C4水平方面,C组患者和A组患者比较,A组患者显著较C组患者高,差异有统计学意义(P<0.05),但是C组患者和B组患者比较,组间数据差异无统计学意义(P>0.05)。在IgA水平方面,C组患者和B组患者比较,组间数据差异无统计学意义(P>0.05),但是C组患者和A组患者比较,A组患者明显较C组患者低,差异有统计学意义(P<0.05);在IgG水平方面,C组患者和A组患者比较,A组患者显著较C组患者高,差异有统计学意义(P<0.05),但是C组患者和B组患者比较,B组患者显著较C组患者低,差异有统计学意义(P<0.05);在IgM水平方面,C组患者和A组以及B组患者比较,A、B两组患者显著较C组患者低,差异有统计学意义(P<0.05)。结论对于乙肝肝硬化合并糖尿病患者,积极对其开展免疫球蛋白及补体检测有利于为临床治疗带来相应的科学指导依据,检测价值显著。

Objective To analyze the value of immunoglobulin and complement detection in patients with hepatitis B liver cirrhosis and diabetes.Methods Thirty-three patients with hepatitis B cirrhosis,diabetes,and hepatitis B cirrhosis with diabetes who were admitted to the hospital from April 2018 to April 2020 were treated as research subjects and classified into three groups,A,B,and C.Three groups of patients were collected.The venous blood was tested for immunoglobulin and complement levels,and the differences in the test results of the three groups of patients were compared.Results In terms of complement C3 levels,there was no statistically significant difference in data between group C and group A patients(P>0.05),but compared with group C and group B patients,group B patients were significantly higher than group C patients,and the difference was statistically significant(P<0.05).In terms of complement C4 level,compared with group C patients,group A patients were significantly higher than group C patients,and the difference was statistically significant(P<0.05),but there was no statistically significant difference in data between group C patients and group B patients(P>0.05).In terms of IgA levels,comparing patients in group C and patients in group B,there was no statistically significant difference in data between the groups(P>0.05).However,comparing patients in group C and patients in group A,patients in group A were significantly lower than those in group C,and the difference was statistically significant(P<0.05).In terms of IgG levels,compared with patients in group C and group A,patients in group A were significantly higher than patients in group C,and the difference was statistically significant(P<0.05),but compared with patients in group C and group B,patients in group B were significantly higher than patients in group C,and the difference was statistically significant(P<0.05);in terms of IgM levels,compared with patients in group A and group B,patients in group A and B were significantly lower than patients in group C,and the difference was statistically significant(P<0.05).Conclusion For patients with hepatitis B liver cirrhosis and diabetes,active ly carrying out immunoglobulin and complement testing will help bring corresponding scientific guidance basis for clinical treatment,and the testing value is significant.